High-Flow Nasal Cannula

Conventional oxygen therapy via nasal prongs or face mask was limited to flow rates of 6-15 L/min, with higher flows causing mucosal drying, discomfort, and imprecise FiO2 delivery. Patients with acute hypoxemic respiratory failure (AHRF) who failed conventional oxygen had only two escalation options: non-invasive ventilation (NIV, often poorly tolerated with high failure rates in non-COPD patients) or intubation with invasive mechanical ventilation. High-flow nasal cannula (HFNC) systems, delivering heated humidified gas at 30-60 L/min through wide-bore nasal prongs, emerged in the 2000s as a novel modality that could deliver precise FiO2, generate low-level PEEP (2-5 cmH2O), reduce anatomical dead space, and improve mucociliary clearance. Early physiological studies demonstrated reduced work of breathing and improved oxygenation compared to conventional oxygen, generating enthusiasm for a gentler escalation pathway.

The FLORALI trial (Frat et al., 2015) was the landmark study that established HFNC as a major respiratory support modality. This multicenter RCT of 310 patients with acute hypoxemic respiratory failure (P/F ≤300) demonstrated that HFNC reduced 90-day mortality to 12% versus 23% for standard oxygen and 28% for NIV (p=0.009 for HFNC vs standard O2, p=0.006 for HFNC vs NIV in the P/F ≤200 subgroup). While the primary endpoint (intubation rate) did not reach statistical significance overall, the mortality benefit in the most hypoxemic patients was striking and biologically plausible — HFNC provided comfortable, sustained oxygenation support that avoided both the risks of delayed intubation and the complications of NIV (gastric distension, mask intolerance, patient-ventilator asynchrony). The FLORALI trial single-handedly drove worldwide adoption of HFNC in ICUs and emergency departments.

HFNC applications expanded rapidly beyond initial AHRF. The OPERA trial and subsequent studies established HFNC as effective prophylactic therapy post-extubation, with the HIGH trial (n=1,101) and NOTUB trial demonstrating reduced reintubation rates in high-risk patients compared to conventional oxygen. The COVID-19 pandemic massively accelerated HFNC adoption globally, with the RECOVERY-RS and HiFLO-COVID trials demonstrating that HFNC reduced intubation rates and improved outcomes in COVID-associated AHRF. The ROX index (SpO2/FiO2 to respiratory rate ratio), first validated by Roca et al. in 2019, provided a simple bedside tool to predict HFNC failure at 2, 6, and 12 hours — a ROX index <2.85 at 2 hours, <3.47 at 6 hours, or <3.85 at 12 hours predicted the need for intubation with good sensitivity, enabling earlier escalation decisions. HFNC also found applications in procedural sedation, pre-oxygenation for intubation, and palliative care.

The Surviving Sepsis Campaign 2021 guidelines recommend HFNC over conventional oxygen for adults with sepsis-induced hypoxemic respiratory failure. The ERS/ATS 2023 guidelines for acute respiratory failure position HFNC as the preferred initial respiratory support modality for acute hypoxemic respiratory failure (non-COPD), ahead of NIV. The WHO COVID-19 clinical management guidelines recommended HFNC as the preferred first escalation for COVID-associated hypoxemia. Guidelines universally emphasize close monitoring during HFNC therapy, with frequent reassessment (ROX index at 2, 6, 12 hours) to avoid delaying intubation when HFNC is failing. The optimal timing of HFNC initiation, escalation thresholds, and combination with awake prone positioning remain areas of active guideline development.

HFNC has become a ubiquitous respiratory support modality in 2025-2026, used in ICUs, emergency departments, respiratory wards, and even pre-hospital settings. The COVID-19 pandemic permanently expanded its availability and clinician familiarity. Current research is refining its role: the HELMET-COVID trial explored helmet NIV versus HFNC; awake prone positioning combined with HFNC (APRONOX, PRONE-COVID) showed promise for delaying intubation; and ongoing studies examine HFNC in acute exacerbations of COPD as an alternative to NIV. The ROX index and similar prediction tools are being integrated into electronic medical record systems for automated escalation alerts. Equipment advances include integration with respiratory monitoring platforms, improved humidification systems, and portable units for transport and pre-hospital use. The key clinical challenge remains appropriate patient selection and avoiding the trap of 'happy hypoxemia' — patients who appear comfortable on HFNC but are deteriorating and need timely intubation.